Description
Book SynopsisThis book presents a contemporary review of the field of pain therapeutics, including the historical medicines which still dominate standard of care treatments, as well as the new mechanisms and combinations/reformulations that have dominated the regulatory approvals over the last decade. In addition, it provides a deep review of the key biological mechanisms currently under investigation for their utility into the treatment of pain, such as ion channels, opiates and others. Additional discussion highlights the current challenges of pain research, covering a range of topics from difficulties in identifying new targets and pre-clinical models to the current regulatory and commercial challenges. This background sets the scene for recent scientific developments in pain research, such as the drive for genetic validation of targets and the derivation of human cell platforms from stem cells. Finally, the book covers the discovery and development stories of two pain products approved in the last decade. These case studies for Lyrica and the Butrans patch, give insight into the discovery and development challenges and successes for both an oral and non-oral product.
Trade Review"The inclusion of information on clinical trial status and typical dosages for approved drugs also make this book interesting to clinical scientists and those involved in the treatment of pain patients. Each chapter contains a thoughtful introduction and conclusion along with general pharmacology needed to understand the activity, and a discussion of some of the major areas of pharmaceutical research." "Overall, the book does a good job of consolidating a wide range of pain topics into a single easily accessible volume." "This book is a well-balanced reference manual for new entrants into pain drug discovery or a general resource for the overview of the current state of pain therapeutics for more experienced researchers." "This compilation does an excellent job of addressing the current state of the field and known targets for the development of pain therapeutics." -- Professor Kevin Tidgewell * ChemMedChem *
Table of ContentsThe Disease of Pain and Current Market Trends; Oral Opiods; Anti-inflammatory drugs; Ion Channel Modulators; Neurotransmitters and Other Non-Opiate Central Mechanisms; Biotherapeutics for the Treatment of Pain; Peptide Therapeutics from Venomous Creatures; Non Oral Treatments for Pain; Affective and Cognitive Modulation of Pain; Pain Management Companies; Enabling Next Generation Pain Therapeutics through Precision Medicine; Case study:-Discovery and Development of Pregabalin; Case Study:-Discovery and Development of the Butrans Patch
